|
- VIVUS: Advancing Innovative Clinical Therapies
With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases
- VIVUS Announces Enrollment of First Patient in Phase 2
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs
- VIVUS Provides Update on Pipeline and Program Milestones
VIVUS has a planned goal of providing access to QSYMIA® for a billion plus people across the globe by the end of 2025 ”
- VIVUS Products - Americas
VIVUS is dedicated to meeting the needs and improving quality of life of patients with serious medical conditions and life-limiting diseases View our approved products in the following countries
- Website And Mobile App Development- Los Angeles | Vivus Tech
Vivus is a digital product development firm specializing in custom website and mobile app development, web design, UI UX design, and machine learning
- Vivus - 2025 Company Profile Team - Tracxn
Vivus is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health
- VIVUS LLC - LinkedIn
With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting
- VIVUS Product Pipleline
VIVUS is not making its unapproved drugs available on an expanded access basis at this time If you have any questions about VIVUS’ expanded access policy, please contact VIVUS Medical Affairs at 1-888-998-4887 or email: vivus@druginfo com
|
|
|